Valentin Fuster, M.D., Ph.D. N Engl J Med 2010; 363:976-977, September 2, 2010
Aspirin and clopidogrel are mainstays of therapy for patients presenting with an acute coronary syndrome. National guidelines dictate that at the time of the patient’s presentation to an emergency department, these therapies should be given expeditiously, whether or not percutaneous coronary intervention is planned.
In this issue of the Journal, Mehta et al. report on the results of the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT–OASIS 7) trial, which evaluated alternative dosing regimens for both of these agents.1
Weblink here